Health Trials

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

ConditionsLeukemiaAcute Myeloid Leukemia in RemissionMyelodysplasiaAcute Lymphoblastic Leukemia in RemissionChronic Myelogenous Leukemia - Chronic PhaseChronic Myelogenous Leukemia, Accelerated PhaseChronic Myelogenous Leukemia With Crisis of Blast CellsBiphenotypic Acute LeukemiaLymphoblastic LymphomaBurkitt LymphomaBurkitt LeukemiaLymphoma After RelapseOther Malignant Hematologic Diseases in Remission
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age0-25
SponsorMedical College of Wisconsin

About this trial

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

Eligibility criteria

Qualifiers

Patient age < 25 years. Both genders and all races eligible.

Disease eligibility

Acute myeloid leukemia, primary or secondary - Disease status: MRD negative (flow MRD ≤ 0.1%)

Myelodysplasia

Disqualifiers

Patients who do not meet disease, organ, or infectious criteria.

No suitable donor

Pregnant or lactating patients are ineligible as many of the medications used in this protocol could be harmful to unborn children and infants

Receiving concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy for treatment of disease other than is specified in the protocol. Maintenance or other post-HCT therapy can be considered after discussion with the study PI.

Trial design

Treatments tested in this trial

  • Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)

Treatment groups

40 Participants
are divided into 1 treatment group

Sponsors and collaborators

Medical College of Wisconsin

Lead sponsor

Source ClinicalTrials.gov